{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=53",
    "query": {
      "condition": "Hematologic",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 10741,
    "total_pages": 1075,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=54&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic&page=52&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T06:58:39.863Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00054431",
      "title": "Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Chronic Myelogenous Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Relapsing Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "2003-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-23",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054431"
    },
    {
      "nct_id": "NCT02953223",
      "title": "A Study to Monitor the Use of an Amino Acid-Based Infant Formula",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cow's Milk Protein Allergy",
        "Eosinophilic Gastrointestinal Disorders",
        "Malabsorption/Maldigestion",
        "Short Bowel Syndrome",
        "Multiple Food Allergies"
      ],
      "interventions": [
        {
          "name": "Free amino acid infant formula",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Société des Produits Nestlé (SPN)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "1 Day to 12 Months"
      },
      "enrollment_count": 144,
      "start_date": "2017-01",
      "completion_date": "2019-01",
      "has_results": false,
      "last_update_posted_date": "2020-02-11",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 29,
      "location_summary": "Lakeside, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more",
      "locations": [
        {
          "city": "Lakeside",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Roseville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02953223"
    },
    {
      "nct_id": "NCT02637427",
      "title": "Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Blood Coagulation Disorders",
        "Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Fresh frozen plasma transfusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2016-02-26",
      "completion_date": "2020-11",
      "has_results": true,
      "last_update_posted_date": "2021-08-18",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637427"
    },
    {
      "nct_id": "NCT06466122",
      "title": "Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Kerry Rogers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-11-07",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06466122"
    },
    {
      "nct_id": "NCT00989586",
      "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "milatuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "veltuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Correlative/Special Studies",
          "type": "PROCEDURE"
        },
        {
          "name": "Quantitative T-, B-, and NK cell subsets",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacokinetics",
          "type": "PROCEDURE"
        },
        {
          "name": "Human Anti-Human Antibodies",
          "type": "PROCEDURE"
        },
        {
          "name": "veltuzumab and milatuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Beth Christian",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2009-09",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-02-06",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00989586"
    },
    {
      "nct_id": "NCT04818970",
      "title": "Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Covid19",
        "Corona Virus Infection",
        "Autoimmune Diseases",
        "Coagulation Disorder, Blood"
      ],
      "interventions": [
        {
          "name": "Narrow Band ultraviolet B-Band Light",
          "type": "DEVICE"
        },
        {
          "name": "non Narrow Band ultraviolet B-Band Light",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cytokind, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "50 Years to 110 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-05-21",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04818970"
    },
    {
      "nct_id": "NCT05102656",
      "title": "Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19 Infection",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Discussion",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2021-06-02",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05102656"
    },
    {
      "nct_id": "NCT06799195",
      "title": "Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies",
        "Graft-versus-Host Disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Attenuated-dose Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "High-dose Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil (MMF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2025-06-23",
      "completion_date": "2031-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06799195"
    },
    {
      "nct_id": "NCT02319369",
      "title": "Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Milademetan",
          "type": "DRUG"
        },
        {
          "name": "AZA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2014-11-25",
      "completion_date": "2020-08-21",
      "has_results": true,
      "last_update_posted_date": "2021-10-11",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 5,
      "location_summary": "Duarte, California • San Francisco, California • Fairway, Kansas + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02319369"
    },
    {
      "nct_id": "NCT05730205",
      "title": "Effects of the Contraceptive Implant in Women With Sickle Cell Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Nexplanon 68 MG Drug Implant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2023-08-02",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-10-15T06:58:39.863Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05730205"
    }
  ]
}